|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||56.60 - 57.94|
|52-week range||55.07 - 127.20|
|Beta (5Y monthly)||0.91|
|PE ratio (TTM)||10.44|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.